Compile Data Set for Download or QSAR

Found 146 hits Enz. Inhib. hit(s) with all data for assayid = 1 entry = 1277   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Plasma kallikrein (Homo sapiens (Human))	BDBM283363 (N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)- 2-((...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3c(C)cc(N)nc3C)cc2c1)S(C)(=O)=O Show InChI InChI=1S/C26H27N5O3S/c1-15-7-20-9-18(11-23(35(4,33)34)25(20)29-13-15)10-21-12-19(5-6-28-21)26(32)30-14-22-16(2)8-24(27)31-17(22)3/h5-9,11-13H,10,14H2,1-4H3,(H2,27,31)(H,30,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283364 (N-((1-aminoisoquinolin-6-yl)methyl)-2-((3- methyl-...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3ccc4c(N)nccc4c3)cc2c1)S(C)(=O)=O Show InChI InChI=1S/C28H25N5O3S/c1-17-9-22-11-19(13-25(37(2,35)36)26(22)32-15-17)12-23-14-21(6-7-30-23)28(34)33-16-18-3-4-24-20(10-18)5-8-31-27(24)29/h3-11,13-15H,12,16H2,1-2H3,(H2,29,31)(H,33,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283365 (N-((3-chloro-6-fluoro-1H-indol-5-yl)methyl)-2- ((3...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cc4c(Cl)c[nH]c4cc3F)cc2c1)S(C)(=O)=O Show InChI InChI=1S/C27H22ClFN4O3S/c1-15-5-18-6-16(8-25(37(2,35)36)26(18)32-12-15)7-20-9-17(3-4-30-20)27(34)33-13-19-10-21-22(28)14-31-24(21)11-23(19)29/h3-6,8-12,14,31H,7,13H2,1-2H3,(H,33,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283366 (N-((6-fluoro-1H-indol-5-yl)methyl)-2-((3- methyl-8...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cc4cc[nH]c4cc3F)cc2c1)S(C)(=O)=O Show InChI InChI=1S/C27H23FN4O3S/c1-16-7-20-8-17(10-25(36(2,34)35)26(20)31-14-16)9-22-12-19(4-5-29-22)27(33)32-15-21-11-18-3-6-30-24(18)13-23(21)28/h3-8,10-14,30H,9,15H2,1-2H3,(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283367 (N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cnc4[nH]cc(Cl)c4c3)cc2c1)S(C)(=O)=O Show InChI InChI=1S/C26H22ClN5O3S/c1-15-5-19-6-16(9-23(36(2,34)35)24(19)29-11-15)7-20-10-18(3-4-28-20)26(33)32-13-17-8-21-22(27)14-31-25(21)30-12-17/h3-6,8-12,14H,7,13H2,1-2H3,(H,30,31)(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283368 (N-((5-chloro-1H-indazol-3-yl)methyl)-2-((3- methyl...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3n[nH]c4ccc(Cl)cc34)cc2c1)S(C)(=O)=O Show InChI InChI=1S/C26H22ClN5O3S/c1-15-7-18-8-16(10-24(36(2,34)35)25(18)29-13-15)9-20-11-17(5-6-28-20)26(33)30-14-23-21-12-19(27)3-4-22(21)31-32-23/h3-8,10-13H,9,14H2,1-2H3,(H,30,33)(H,31,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283369 (N-((3-chloro-4-fluoro-1H-indol-5-yl)methyl)-2- ((3...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3ccc4[nH]cc(Cl)c4c3F)cc2c1)S(C)(=O)=O Show InChI InChI=1S/C27H22ClFN4O3S/c1-15-7-19-8-16(10-23(37(2,35)36)26(19)32-12-15)9-20-11-17(5-6-30-20)27(34)33-13-18-3-4-22-24(25(18)29)21(28)14-31-22/h3-8,10-12,14,31H,9,13H2,1-2H3,(H,33,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283377 (N-((6-amino-4-methylpyridin-3-yl)methyl)-2- ((3-ch...) Show SMILES Cc1cc(N)ncc1CNC(=O)c1ccnc(Cc2ccc3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C23H20ClN5O/c1-14-6-22(25)28-11-18(14)12-29-23(30)16-4-5-26-20(10-16)8-15-2-3-21-17(7-15)9-19(24)13-27-21/h2-7,9-11,13H,8,12H2,1H3,(H2,25,28)(H,29,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283379 (N-((1-aminoisoquinolin-6-yl)methyl)-2-((3- chloroq...) Show SMILES Nc1nccc2cc(CNC(=O)c3ccnc(Cc4ccc5ncc(Cl)cc5c4)c3)ccc12 Show InChI InChI=1S/C26H20ClN5O/c27-21-12-20-9-16(2-4-24(20)31-15-21)11-22-13-19(6-7-29-22)26(33)32-14-17-1-3-23-18(10-17)5-8-30-25(23)28/h1-10,12-13,15H,11,14H2,(H2,28,30)(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283381 (N-((3-chloro-6-fluoro-1H-indol-5-yl)methyl)-2- ((3...) Show SMILES Fc1cc2[nH]cc(Cl)c2cc1CNC(=O)c1ccnc(Cc2ccc3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C25H17Cl2FN4O/c26-18-7-16-5-14(1-2-23(16)30-12-18)6-19-8-15(3-4-29-19)25(33)32-11-17-9-20-21(27)13-31-24(20)10-22(17)28/h1-5,7-10,12-13,31H,6,11H2,(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283382 (N-((6-amino-2-methylpyridin-3-yl)methyl)-2- ((3-ch...) Show SMILES Cc1nc(N)ccc1CNC(=O)c1ccnc(Cc2ccc3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C23H20ClN5O/c1-14-17(3-5-22(25)29-14)12-28-23(30)16-6-7-26-20(11-16)9-15-2-4-21-18(8-15)10-19(24)13-27-21/h2-8,10-11,13H,9,12H2,1H3,(H2,25,29)(H,28,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283383 (N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)- 2-((...) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1ccnc(Cc2ccc3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C24H22ClN5O/c1-14-7-23(26)30-15(2)21(14)13-29-24(31)17-5-6-27-20(11-17)9-16-3-4-22-18(8-16)10-19(25)12-28-22/h3-8,10-12H,9,13H2,1-2H3,(H2,26,30)(H,29,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283385 (N-((5-chloro-1H-indazol-3-yl)methyl)-2-((3- chloro...) Show SMILES Clc1ccc2[nH]nc(CNC(=O)c3ccnc(Cc4ccc5ncc(Cl)cc5c4)c3)c2c1 Show InChI InChI=1S/C24H17Cl2N5O/c25-17-2-4-22-20(11-17)23(31-30-22)13-29-24(32)15-5-6-27-19(10-15)8-14-1-3-21-16(7-14)9-18(26)12-28-21/h1-7,9-12H,8,13H2,(H,29,32)(H,30,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283386 (N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...) Show SMILES Clc1c[nH]c2ncc(CNC(=O)c3ccnc(Cc4ccc5ncc(Cl)cc5c4)c3)cc12 Show InChI InChI=1S/C24H17Cl2N5O/c25-18-8-17-5-14(1-2-22(17)28-12-18)6-19-9-16(3-4-27-19)24(32)31-11-15-7-20-21(26)13-30-23(20)29-10-15/h1-5,7-10,12-13H,6,11H2,(H,29,30)(H,31,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283382 (N-((6-amino-2-methylpyridin-3-yl)methyl)-2- ((3-ch...) Show SMILES Cc1nc(N)ccc1CNC(=O)c1ccnc(Cc2ccc3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C23H20ClN5O/c1-14-17(3-5-22(25)29-14)12-28-23(30)16-6-7-26-20(11-16)9-15-2-4-21-18(8-15)10-19(24)13-27-21/h2-8,10-11,13H,9,12H2,1H3,(H2,25,29)(H,28,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283388 (N-((3-chloro-4-fluoro-1H-indol-5-yl)methyl)-2- ((3...) Show SMILES Fc1c(CNC(=O)c2ccnc(Cc3ccc4ncc(Cl)cc4c3)c2)ccc2[nH]cc(Cl)c12 Show InChI InChI=1S/C25H17Cl2FN4O/c26-18-9-17-7-14(1-3-21(17)30-12-18)8-19-10-15(5-6-29-19)25(33)32-11-16-2-4-22-23(24(16)28)20(27)13-31-22/h1-7,9-10,12-13,31H,8,11H2,(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283394 (N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)- 2-((...) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1ccnc(Cc2ccc3nc(CN)ccc3c2)c1 Show InChI InChI=1S/C25H26N6O/c1-15-9-24(27)30-16(2)22(15)14-29-25(32)19-7-8-28-21(12-19)11-17-3-6-23-18(10-17)4-5-20(13-26)31-23/h3-10,12H,11,13-14,26H2,1-2H3,(H2,27,30)(H,29,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283397 (N-((3-chloro-6-fluoro-1H-indol-5-yl)methyl)-2- ((3...) Show SMILES Fc1cc2[nH]cc(Cl)c2cc1CNC(=O)c1ccnc(Cc2cc(C#N)c3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C26H16Cl2FN5O/c27-19-6-16-3-14(4-17(10-30)25(16)33-12-19)5-20-7-15(1-2-31-20)26(35)34-11-18-8-21-22(28)13-32-24(21)9-23(18)29/h1-4,6-9,12-13,32H,5,11H2,(H,34,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283398 (N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)- 2-((...) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1ccnc(Cc2cc(C#N)c3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C25H21ClN6O/c1-14-5-23(28)32-15(2)22(14)13-31-25(33)17-3-4-29-21(10-17)8-16-6-18-9-20(26)12-30-24(18)19(7-16)11-27/h3-7,9-10,12H,8,13H2,1-2H3,(H2,28,32)(H,31,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283399 (N-((3-chloro-4-fluoro-1H-indol-5-yl)methyl)-2- ((3...) Show SMILES Fc1c(CNC(=O)c2ccnc(Cc3cc(C#N)c4ncc(Cl)cc4c3)c2)ccc2[nH]cc(Cl)c12 Show InChI InChI=1S/C26H16Cl2FN5O/c27-19-8-17-5-14(6-18(10-30)25(17)33-12-19)7-20-9-15(3-4-31-20)26(35)34-11-16-1-2-22-23(24(16)29)21(28)13-32-22/h1-6,8-9,12-13,32H,7,11H2,(H,34,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283400 (2-((3-chloro-8-cyanoquinolin-6-yl)methyl)-N- ((6-f...) Show SMILES Fc1cc2[nH]ccc2cc1CNC(=O)c1ccnc(Cc2cc(C#N)c3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C26H17ClFN5O/c27-21-9-18-5-15(6-19(12-29)25(18)32-14-21)7-22-10-17(2-3-30-22)26(34)33-13-20-8-16-1-4-31-24(16)11-23(20)28/h1-6,8-11,14,31H,7,13H2,(H,33,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283402 (N-((5-chloro-1H-indazol-3-yl)methyl)-2-((3- chloro...) Show SMILES Clc1ccc2[nH]nc(CNC(=O)c3ccnc(Cc4cc(C#N)c5ncc(Cl)cc5c4)c3)c2c1 Show InChI InChI=1S/C25H16Cl2N6O/c26-18-1-2-22-21(10-18)23(33-32-22)13-31-25(34)15-3-4-29-20(9-15)7-14-5-16-8-19(27)12-30-24(16)17(6-14)11-28/h1-6,8-10,12H,7,13H2,(H,31,34)(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283403 (N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...) Show SMILES Clc1c[nH]c2ncc(CNC(=O)c3ccnc(Cc4cc(C#N)c5ncc(Cl)cc5c4)c3)cc12 Show InChI InChI=1S/C25H16Cl2N6O/c26-19-7-17-3-14(4-18(9-28)23(17)30-12-19)5-20-8-16(1-2-29-20)25(34)33-11-15-6-21-22(27)13-32-24(21)31-10-15/h1-4,6-8,10,12-13H,5,11H2,(H,31,32)(H,33,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283404 (N-((6-amino-2-methylpyridin-3-yl)methyl)-2- ((3-ch...) Show SMILES Cc1nc(N)ccc1CNC(=O)c1ccnc(Cc2cc(C#N)c3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C24H19ClN6O/c1-14-17(2-3-22(27)31-14)12-30-24(32)16-4-5-28-21(10-16)8-15-6-18-9-20(25)13-29-23(18)19(7-15)11-26/h2-7,9-10,13H,8,12H2,1H3,(H2,27,31)(H,30,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283405 (N-((1-aminoisoquinolin-6-yl)methyl)-2-((3- chloro-...) Show SMILES Nc1nccc2cc(CNC(=O)c3ccnc(Cc4cc(C#N)c5ncc(Cl)cc5c4)c3)ccc12 Show InChI InChI=1S/C27H19ClN6O/c28-22-11-20-8-17(9-21(13-29)25(20)33-15-22)10-23-12-19(4-5-31-23)27(35)34-14-16-1-2-24-18(7-16)3-6-32-26(24)30/h1-9,11-12,15H,10,14H2,(H2,30,32)(H,34,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283406 (6-((4-(((6-amino-2,4-dimethylpyridin-3- yl)methyl)...) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1ccnc(Cc2cc(C(N)=O)c3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C25H23ClN6O2/c1-13-5-22(27)32-14(2)21(13)12-31-25(34)16-3-4-29-19(10-16)7-15-6-17-9-18(26)11-30-23(17)20(8-15)24(28)33/h3-6,8-11H,7,12H2,1-2H3,(H2,27,32)(H2,28,33)(H,31,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283407 (3-chloro-6-((4-(((3-chloro-6-fluoro-1H-indol-5- yl...) Show SMILES NC(=O)c1cc(Cc2cc(ccn2)C(=O)NCc2cc3c(Cl)c[nH]c3cc2F)cc2cc(Cl)cnc12 Show InChI InChI=1S/C26H18Cl2FN5O2/c27-17-6-15-3-13(5-20(25(30)35)24(15)33-11-17)4-18-7-14(1-2-31-18)26(36)34-10-16-8-19-21(28)12-32-23(19)9-22(16)29/h1-3,5-9,11-12,32H,4,10H2,(H2,30,35)(H,34,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283408 (3-chloro-6-((4-(((5-chloro-1H-indazol-3- yl)methyl...) Show SMILES NC(=O)c1cc(Cc2cc(ccn2)C(=O)NCc2n[nH]c3ccc(Cl)cc23)cc2cc(Cl)cnc12 Show InChI InChI=1S/C25H18Cl2N6O2/c26-16-1-2-21-19(10-16)22(33-32-21)12-31-25(35)14-3-4-29-18(9-14)6-13-5-15-8-17(27)11-30-23(15)20(7-13)24(28)34/h1-5,7-11H,6,12H2,(H2,28,34)(H,31,35)(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283409 (3-chloro-6-((4-(((3-chloro-1H-pyrrolo[2,3- b]pyrid...) Show SMILES NC(=O)c1cc(Cc2cc(ccn2)C(=O)NCc2cnc3[nH]cc(Cl)c3c2)cc2cc(Cl)cnc12 Show InChI InChI=1S/C25H18Cl2N6O2/c26-17-7-16-3-13(5-20(23(28)34)22(16)30-11-17)4-18-8-15(1-2-29-18)25(35)33-10-14-6-19-21(27)12-32-24(19)31-9-14/h1-3,5-9,11-12H,4,10H2,(H2,28,34)(H,31,32)(H,33,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283410 (6-((4-(((6-amino-2-methylpyridin-3- yl)methyl)carb...) Show SMILES Cc1nc(N)ccc1CNC(=O)c1ccnc(Cc2cc(C(N)=O)c3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C24H21ClN6O2/c1-13-16(2-3-21(26)31-13)11-30-24(33)15-4-5-28-19(10-15)7-14-6-17-9-18(25)12-29-22(17)20(8-14)23(27)32/h2-6,8-10,12H,7,11H2,1H3,(H2,26,31)(H2,27,32)(H,30,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283411 (6-((4-(((6-amino-4-methylpyridin-3- yl)methyl)carb...) Show SMILES Cc1cc(N)ncc1CNC(=O)c1ccnc(Cc2cc(C(N)=O)c3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C24H21ClN6O2/c1-13-4-21(26)29-10-17(13)11-31-24(33)15-2-3-28-19(9-15)6-14-5-16-8-18(25)12-30-22(16)20(7-14)23(27)32/h2-5,7-10,12H,6,11H2,1H3,(H2,26,29)(H2,27,32)(H,31,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283412 (6-((4-(((1-aminoisoquinolin-6- yl)methyl)carbamoyl...) Show SMILES NC(=O)c1cc(Cc2cc(ccn2)C(=O)NCc2ccc3c(N)nccc3c2)cc2cc(Cl)cnc12 Show InChI InChI=1S/C27H21ClN6O2/c28-20-11-19-8-16(10-23(26(30)35)24(19)33-14-20)9-21-12-18(4-5-31-21)27(36)34-13-15-1-2-22-17(7-15)3-6-32-25(22)29/h1-8,10-12,14H,9,13H2,(H2,29,32)(H2,30,35)(H,34,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283413 (3-chloro-6-((4-(((3-chloro-4-fluoro-1H-indol-5- yl...) Show SMILES NC(=O)c1cc(Cc2cc(ccn2)C(=O)NCc2ccc3[nH]cc(Cl)c3c2F)cc2cc(Cl)cnc12 Show InChI InChI=1S/C26H18Cl2FN5O2/c27-17-8-16-5-13(7-19(25(30)35)24(16)33-11-17)6-18-9-14(3-4-31-18)26(36)34-10-15-1-2-21-22(23(15)29)20(28)12-32-21/h1-5,7-9,11-12,32H,6,10H2,(H2,30,35)(H,34,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283414 (3-chloro-6-((4-(((6-fluoro-1H-indol-5- yl)methyl)c...) Show SMILES NC(=O)c1cc(Cc2cc(ccn2)C(=O)NCc2cc3cc[nH]c3cc2F)cc2cc(Cl)cnc12 Show InChI InChI=1S/C26H19ClFN5O2/c27-19-9-17-5-14(7-21(25(29)34)24(17)32-13-19)6-20-10-16(2-3-30-20)26(35)33-12-18-8-15-1-4-31-23(15)11-22(18)28/h1-5,7-11,13,31H,6,12H2,(H2,29,34)(H,33,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283415 (N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)- 2-((...) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1ccnc(Cc2cc(c3ncc(Cl)cc3c2)S(C)(=O)=O)c1 Show InChI InChI=1S/C25H24ClN5O3S/c1-14-6-23(27)31-15(2)21(14)13-30-25(32)17-4-5-28-20(11-17)8-16-7-18-10-19(26)12-29-24(18)22(9-16)35(3,33)34/h4-7,9-12H,8,13H2,1-3H3,(H2,27,31)(H,30,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283416 (N-((3-chloro-6-fluoro-1H-indol-5-yl)methyl)-2- ((3...) Show SMILES CS(=O)(=O)c1cc(Cc2cc(ccn2)C(=O)NCc2cc3c(Cl)c[nH]c3cc2F)cc2cc(Cl)cnc12 Show InChI InChI=1S/C26H19Cl2FN4O3S/c1-37(35,36)24-6-14(4-16-7-18(27)12-32-25(16)24)5-19-8-15(2-3-30-19)26(34)33-11-17-9-20-21(28)13-31-23(20)10-22(17)29/h2-4,6-10,12-13,31H,5,11H2,1H3,(H,33,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283417 (N-((6-amino-2-methylpyridin-3-yl)methyl)-2- ((3-ch...) Show SMILES Cc1nc(N)ccc1CNC(=O)c1ccnc(Cc2cc(c3ncc(Cl)cc3c2)S(C)(=O)=O)c1 Show InChI InChI=1S/C24H22ClN5O3S/c1-14-17(3-4-22(26)30-14)12-29-24(31)16-5-6-27-20(11-16)8-15-7-18-10-19(25)13-28-23(18)21(9-15)34(2,32)33/h3-7,9-11,13H,8,12H2,1-2H3,(H2,26,30)(H,29,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283418 (N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)- 2-((...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3c(C)cc(N)nc3C)cc2c1)C#N Show InChI InChI=1S/C26H24N6O/c1-15-6-20-8-18(9-21(12-27)25(20)30-13-15)10-22-11-19(4-5-29-22)26(33)31-14-23-16(2)7-24(28)32-17(23)3/h4-9,11,13H,10,14H2,1-3H3,(H2,28,32)(H,31,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283419 (N-((1-aminoisoquinolin-6-yl)methyl)-2-((8- cyano-3...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3ccc4c(N)nccc4c3)cc2c1)C#N Show InChI InChI=1S/C28H22N6O/c1-17-8-22-10-19(11-23(14-29)26(22)33-15-17)12-24-13-21(5-6-31-24)28(35)34-16-18-2-3-25-20(9-18)4-7-32-27(25)30/h2-11,13,15H,12,16H2,1H3,(H2,30,32)(H,34,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283420 (N-((3-chloro-6-fluoro-1H-indol-5-yl)methyl)-2- ((8...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cc4c(Cl)c[nH]c4cc3F)cc2c1)C#N Show InChI InChI=1S/C27H19ClFN5O/c1-15-4-18-5-16(6-19(11-30)26(18)33-12-15)7-21-8-17(2-3-31-21)27(35)34-13-20-9-22-23(28)14-32-25(22)10-24(20)29/h2-6,8-10,12,14,32H,7,13H2,1H3,(H,34,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283421 (N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cnc4[nH]cc(Cl)c4c3)cc2c1)C#N Show InChI InChI=1S/C26H19ClN6O/c1-15-4-19-5-16(6-20(10-28)24(19)30-11-15)7-21-9-18(2-3-29-21)26(34)33-13-17-8-22-23(27)14-32-25(22)31-12-17/h2-6,8-9,11-12,14H,7,13H2,1H3,(H,31,32)(H,33,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283422 (N-((3-chloro-4-fluoro-1H-indol-5-yl)methyl)-2- ((8...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3ccc4[nH]cc(Cl)c4c3F)cc2c1)C#N Show InChI InChI=1S/C27H19ClFN5O/c1-15-6-19-7-16(8-20(11-30)26(19)33-12-15)9-21-10-17(4-5-31-21)27(35)34-13-18-2-3-23-24(25(18)29)22(28)14-32-23/h2-8,10,12,14,32H,9,13H2,1H3,(H,34,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283423 (N-((5-chloro-1H-indazol-3-yl)methyl)-2-((8- cyano-...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3n[nH]c4ccc(Cl)cc34)cc2c1)C#N Show InChI InChI=1S/C26H19ClN6O/c1-15-6-18-7-16(8-19(12-28)25(18)30-13-15)9-21-10-17(4-5-29-21)26(34)31-14-24-22-11-20(27)2-3-23(22)32-33-24/h2-8,10-11,13H,9,14H2,1H3,(H,31,34)(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283424 (2-((8-cyano-3-methylquinolin-6-yl)methyl)-N- ((6-f...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cc4cc[nH]c4cc3F)cc2c1)C#N Show InChI InChI=1S/C27H20FN5O/c1-16-6-20-7-17(8-21(13-29)26(20)32-14-16)9-23-11-19(3-4-30-23)27(34)33-15-22-10-18-2-5-31-25(18)12-24(22)28/h2-8,10-12,14,31H,9,15H2,1H3,(H,33,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283425 (6-((4-(((6-amino-2,4-dimethylpyridin-3- yl)methyl)...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3c(C)cc(N)nc3C)cc2c1)C(N)=O Show InChI InChI=1S/C26H26N6O2/c1-14-6-19-8-17(10-21(25(28)33)24(19)30-12-14)9-20-11-18(4-5-29-20)26(34)31-13-22-15(2)7-23(27)32-16(22)3/h4-8,10-12H,9,13H2,1-3H3,(H2,27,32)(H2,28,33)(H,31,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283426 (6-((4-(((3-chloro-6-fluoro-1H-indol-5- yl)methyl)c...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cc4c(Cl)c[nH]c4cc3F)cc2c1)C(N)=O Show InChI InChI=1S/C27H21ClFN5O2/c1-14-4-17-5-15(7-21(26(30)35)25(17)33-11-14)6-19-8-16(2-3-31-19)27(36)34-12-18-9-20-22(28)13-32-24(20)10-23(18)29/h2-5,7-11,13,32H,6,12H2,1H3,(H2,30,35)(H,34,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283427 (6-((4-(((1-aminoisoquinolin-6- yl)methyl)carbamoyl...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3ccc4c(N)nccc4c3)cc2c1)C(N)=O Show InChI InChI=1S/C28H24N6O2/c1-16-8-21-10-18(12-24(27(30)35)25(21)33-14-16)11-22-13-20(5-6-31-22)28(36)34-15-17-2-3-23-19(9-17)4-7-32-26(23)29/h2-10,12-14H,11,15H2,1H3,(H2,29,32)(H2,30,35)(H,34,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283428 (6-((4-(((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)m...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cnc4[nH]cc(Cl)c4c3)cc2c1)C(N)=O Show InChI InChI=1S/C26H21ClN6O2/c1-14-4-18-5-15(7-21(24(28)34)23(18)30-10-14)6-19-9-17(2-3-29-19)26(35)33-12-16-8-20-22(27)13-32-25(20)31-11-16/h2-5,7-11,13H,6,12H2,1H3,(H2,28,34)(H,31,32)(H,33,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283429 (6-((4-(((3-chloro-4-fluoro-1H-indol-5- yl)methyl)c...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3ccc4[nH]cc(Cl)c4c3F)cc2c1)C(N)=O Show InChI InChI=1S/C27H21ClFN5O2/c1-14-6-18-7-15(9-20(26(30)35)25(18)33-11-14)8-19-10-16(4-5-31-19)27(36)34-12-17-2-3-22-23(24(17)29)21(28)13-32-22/h2-7,9-11,13,32H,8,12H2,1H3,(H2,30,35)(H,34,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM283430 (6-((4-(((5-chloro-1H-indazol-3- yl)methyl)carbamoy...) Show SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3n[nH]c4ccc(Cl)cc34)cc2c1)C(N)=O Show InChI InChI=1S/C26H21ClN6O2/c1-14-6-17-7-15(9-21(25(28)34)24(17)30-12-14)8-19-10-16(4-5-29-19)26(35)31-13-23-20-11-18(27)2-3-22(20)32-33-23/h2-7,9-12H,8,13H2,1H3,(H2,28,34)(H,31,35)(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<100	n/a	n/a	n/a	n/a	n/a	n/a
LIFESCI PHARMACEUTICALS, INC. US Patent					Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...				US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 146 total )  |  Next  |  Last  >>

Jump to: